Robert C. Andrews

Rob obtained his Ph.D. at the University of South Carolina in 1986 under the direction of Prof. James Marshall and completed postdoctoral studies in 1988 with Prof. Albert Meyers at Colorado State University. Rob joined Glaxo Research and Development in 1988, pursuing orally active phospholipase A2 inhibitors and therapeutic agents for benign prostatic hyperplasia (BPH). With Glaxo Wellcome Rob progressed to the area of proteases and his team discovered potent inhibitors of tumor necrosis factor – alpha convertase (TACE) possessing oral activity in animal models of inflammatory disease. Rob is the author of numerous papers and presentations, and is an inventor on numerous patents and patent applications.